Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Detailed price information for Vistagen Therapeutics Inc (VTGN-Q) from The Globe and Mail including charting and trades.